Business
Xeris Pharmaceuticals to Announce First Quarter 2020 Financial Results and Host Conference Call on May 7, 2020
CHICAGO--(BUSINESS WIRE)-- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology
About this update from Xeris Biopharma Holdings, Inc.
[{"type":"text","content":"\n \n\n CHICAGO--(BUSINESS WIRE)--\n\nXeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that the Company will release its first quarter 2020 financial results before the opening of the U.S. financial markets on Thursday, May 7, 2020. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company’s financial and operational results.\n\n\nTo participate in the call, please dial (866) 951-8137 (domestic) or (270) 215-9500 (international) referencing conference ID 4666547. The live webcast will be accessible on the Investors section of Xeris’ website, www.xerispharma.com. The webcast will be available on the Company’s website for 30 days following the live call.\n\n\nAbout Xeris Pharmaceuticals, Inc.\n\n\nXeris (Nasdaq: XERS) is a specialty pharmaceutical company delivering innovative solutions to simplify the experience of administering important therapies that people rely on every day around the world.\n\n\nWith a novel technology platform that enables ready-to-use, room-temperature stable formulations of injectable and infusible therapies, the company is advancing a portfolio of solutions in various therapeutic categories, including its first commercial product, Gvoke™. Its proprietary XeriSol™ and XeriJect™ formulation technologies have the potential to offer distinct advantages over conventional product formulations, including eliminating the need for reconstitution, enabling long-term, room-temperature stability, significantly reducing injection volume, and eliminating the requirement for intravenous (IV) infusion. With Xeris’ technology, new product formulations are designed to be easier to use by patients, caregivers, and health practitioners and help reduce costs for payers and the healthcare system.\n\n\nXeris is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on Twitter, LinkedIn or Instagram.\n\n\nForward-Looking Statements \n\n\nAny statements in this press release about future expectations, plans and prospects for Xeris Pharmaceuticals, Inc., including statements regarding the acceptance of Gvoke™ in the marketplace, the market and therapeutic potential of its product ca...